Cell Free DNA (cfDNA) Testing Market Report: Analysis, Share, Trend, Segmentation, Top Leaders, Forecast To 2033

Cell-free DNA (cfDNA) testing is a non-invasive diagnostic method that analyzes DNA fragments circulating freely in the bloodstream. cfDNA testing is utilized in liquid biopsy procedures and allows for detecting and analyzing genetic mutations and alterations without the need for a traditional tissue biopsy.

Sizing and Forecast
The cell free DNA (cfDNA) testing market size has grown exponentially in recent years. It will grow from $7.07 billion in 2023 to $8.74 billion in 2024 at a compound annual growth rate (CAGR) of 23.6%.  The growth in the historic period can be attributed to a rise in the adoption of cfDNA testing in prenatal care, increasing use of cfDNA analysis, growing interest in cfDNA research across various medical fields, and rise in gaining approvals from regulatory bodies.

The cell free DNA (cfDNA) testing market size is expected to see exponential growth in the next few years. It will grow to $20.63 billion in 2028 at a compound annual growth rate (CAGR) of 23.9%.  The growth in the forecast period can be attributed to a shift towards personalized medicine, enhancements in healthcare infrastructure, aging population and increasing incidence of cancer, increasing adoption of precision medicine, increasing awareness and acceptance of liquid biopsy techniques, and increasing investment and funding in cfDNA research. Major trends in the forecast period include adoption of liquid biopsy technologies, advancements in Next-Generation Sequencing (NGS) technology, integration of AI and machine learning in cfDNA testing, development of point-of-care cfDNA tests, and implementation of cloud-based platforms for data storage and analysis.

Order your report now for swift delivery, visit the link:
https://www.thebusinessresearchcompany.com/report/cell-free-dna-cfdna-testing-global-market-report

Segmentation & Regional Insights
The cell free DNA (cfDNA) testing market covered in this report is segmented –
1) By Product: Donor-Derived Cell-Free DNA, Circulating Cell-Free Tumor DNA, Cell-Free Fetal DNA
2) By Platforms:  Next Generation Sequencing (NGS), rPCR And Multiplexed PCR, qPCR And dPCR, Other platforms
3) By Application: Oncology, Non-Invasive Prenatal Test (NIPT), Gynecology, Transplantation, Other Applications

North America was the largest region in the cell-free DNA (cfDNA) testing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell free DNA (cfDNA) testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Intrigued to explore the contents? Secure your hands-on a free sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15757&type=smp

Major Driver Impacting Market Growth
The rising prevalence of cancer is expected to propel the growth of the cell-free DNA (cfDNA) testing market going forward. Cancer is a complex group of diseases characterized by the uncontrolled growth and spread of abnormal cells in the body. These cells can invade and destroy normal tissue and, if not controlled, can significantly harm the body. The prevalence of cancer is due to aging populations, shifts in lifestyle, environmental influences, and advancements in detection and diagnostic techniques. cfDNA testing detects genetic mutations associated with cancer at an early stage, often before symptoms appear. This allows for early intervention, improving patient outcomes and survival rates by identifying cancer in its initial stages. For instance, in February 2024, according to the World Health Organization (WHO), a Switzerland-based intergovernmental organization, there are expected to be over 35 million new cases of cancer in 2050, a 77% increase over the projected 20 million cases in 2022. Therefore, the rising prevalence of cancer is driving the growth of the cell-free DNA (cfDNA) testing market.

Key Industry Players
Major companies operating in the cell free DNA (cfDNA) testing market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Agilent Technologies Inc., Illumina Inc., Qiagen N.V., Exact Sciences Corporation, Bio-Techne Corporation, Natera Inc., Myriad Genetics Inc., NeoGenomics Laboratories Inc., Invitae Corporation, Foundation Medicine Inc., Guardant Health Inc., Integrated DNA Technologies Inc., Caris Life Sciences Inc., Twist Bioscience Corporation, Adaptive Biotechnologies Corporation, Biodesix Inc., Biocept Inc., Personal Genome Diagnostics Inc., Agena Bioscience Inc., Menarini Silicon Biosystems Inc., Circulogene Theranostics LLC

The cell free dna (cfdna) testing market report table of contents includes:
1. Executive Summary
2. Market Characteristics
3. Market Trends And Strategies
4. Impact Of COVID-19
5. Market Size And Growth
6. Segmentation
7. Regional And Country Analysis
……..
27. Competitive Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model